Navigation Links
Researchers identify gene set that shows which patients benefit from chemo after surgery
Date:9/7/2010

Lung cancer researchers have identified a genetic signature that can help doctors determine which patients with early-stage non-small cell lung cancer are at high risk for developing disease recurrence and therefore may benefit from chemotherapy after surgery ("adjuvant chemotherapy").

"The findings give patients and their doctors a clearer map of the appropriate post-operative treatment route to follow. Not all patients benefit from chemotherapy after surgery and those with less aggressive cancer may be spared from the potentially debilitating side effects of this treatment," says principal investigator Dr. Ming Tsao, pathologist at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network (UHN), and Professor of Laboratory Medicine and Pathobiology at the University of Toronto. He also holds the M. Qasim Choksi Chair in Lung Cancer Translational Research at UHN.

"Our study was rigorously validated by multiple testing across data from different patient populations and so we believe these findings can be applied generally to other patients with early-stage non-small cell lung cancer," says Dr. Tsao.

"The ability to tell whether a particular patient is a good candidate for adjuvant chemotherapy will bring us closer to our goals of improving patient care through personalized medicine," adds study collaborator Dr. Frances Shepherd, PMH medical oncologist and holder of the Scott Taylor Chair in Lung Cancer Research at UHN.

The study, published online today in the Journal of Clinical Oncology (JCO 64325), advances the 2005 findings of the NCIC Clinical Trials Group study JBR.10, conducted in collaboration with the U.S. National Cancer Institute. The JBR.10 findings showed significant survival benefit from the anti-cancer drugs vinorelbine and cisplatin in patients with early-stage (stage I and II) non-small cell lung cancer whose tumors had been surgically removed. Dr. Tsao's research team and collaborators at NCIC Clinical Trials Group at Queen's University performed a genetic analysis of tumor tissue from 133 of the 482 patients from the JBR.10 study who had banked frozen tumor samples.

The Tsao team identified a set of 15 genes that, in 62 patients who did not receive chemotherapy after surgery, predicted which patients had aggressive cancers with high risk of recurrence and death (31 patients), and which had less aggressive disease and low risk of recurrence (31 patients).

They then applied the signature to 71 patients who were randomized to receive chemotherapy in the JBR.10 trial. Patients predicted to have aggressive disease experienced the greatest benefit from chemotherapy - with a 67 percent reduction in the risk of death - while chemotherapy did not reduce the risk of death in patients designated as low risk.

While a previous JBR.10 analysis showed that overall only patients with stage II disease benefited from chemotherapy after surgery, Dr. Tsao's study demonstrates that the 15 gene signature may identify patients with both stage I and II cancers who may benefit from post-operative chemotherapy.


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.on.ca
416-946-2846
University Health Network
Source:Eurekalert

Related medicine news :

1. Researchers will test suicide prevention program in high schools
2. Mount Sinai researchers find new target to improve pain management
3. Non-invasive therapy significantly improves depression, UCLA researchers say
4. For the first time, researchers identify and isolate adult mammary stem cells in mice
5. UNH researchers develop improved tool for cycling fitness
6. Sodium MRI gives new insights into detecting osteoarthritis, NYU researchers find
7. Researchers urge reclassification of traumatic brain injury as chronic disease
8. Researchers closer to development of drug to prevent deadly immune response
9. Mayo researchers develop new laboratory cell lines to study treatment for ATC
10. Researchers zero in on protein that destroys HIV
11. 15 new US patents awarded this past year to NJIT researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 19, 2017 , ... A July 5th ... weight loss surgery patients who had received a body contouring procedure reported experiencing a ... clinic Beverly Hills Physicians (BHP), which provides both types of procedures, notes that this ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Fidget”: a fun-filled, action-packed ... retired public high school music and drama teacher who was a summa cum laude ... including a “Teacher of the Year” award. After her retirement from public school, Lynn ...
(Date:7/18/2017)... Oaks, CA (PRWEB) , ... July 18, 2017 , ... ... Ph.D. scientist extracted cannabis oils, announced today that at the WORLDZ Summit, taking place ... will be speaking on the therapeutic benefits of medical cannabis for both pediatric and ...
(Date:7/18/2017)... ... July 18, 2017 , ... ClinicalTrials.gov ... Decisions Do You Need to Consider?, **An FDAnews Webinar**, Aug. 2, 2017 — ... Part 11, “Final Rule for Clinical Trials Registration and Results Information,” is a ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... on a lien basis, partners with the best medical professionals who offer the ... and pre-approves each medical professional in their network, ensuring that each patient receives ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Zymo Research Corp., also known as ,The Epigenetics Company, announced ... in a precise manner using the myDNAge ™ test. Based on ... of human genetics and biostatistics at the David Geffen School of ... Zymo Research,s proprietary DNAge ™ technology is used to analyze DNA ... ...
(Date:7/11/2017)...  The global market for liquid biopsy diagnostic and ... in 2016.  Although in early stages, the global market ... as a result of the gradual shift towards personalized ... of a significant number of new liquid biopsy tests ... biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a ... who suffer from painful intercourse and other painful pelvic pain conditions such ... to menopause. ... LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void ...
Breaking Medicine Technology: